VolitionRX Ltd (NYSEAMERICAN:VNRX) Director Guy Archibald Innes acquired 50,000 shares of the firm’s stock in a transaction on Thursday, August 16th. The shares were bought at an average cost of $2.00 per share, for a total transaction of $100,000.00. The purchase was disclosed in a filing with the SEC, which is available at this hyperlink.

VolitionRX stock traded down $0.10 during trading hours on Monday, reaching $1.76. 1,744 shares of the company’s stock traded hands, compared to its average volume of 111,970. VolitionRX Ltd has a fifty-two week low of $1.44 and a fifty-two week high of $4.00.

VolitionRX (NYSEAMERICAN:VNRX) last released its earnings results on Monday, August 13th. The medical research company reported ($0.15) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.01.

VNRX has been the topic of a number of research reports. Maxim Group initiated coverage on shares of VolitionRX in a research report on Wednesday, May 16th. They set a “buy” rating and a $6.00 target price on the stock. Benchmark restated a “buy” rating and set a $5.00 target price (down from $7.00) on shares of VolitionRX in a research report on Monday, May 14th.

About VolitionRX

VolitionRX Limited, a life sciences company, engages in the development of blood tests to help diagnose a range of cancers worldwide. The company develops 39 epigenetic Nu.Q blood assays based on its Nucleosomics biomarker discovery platform. VolitionRX Limited is based in Singapore.

Read More: Diversification in Your Portfolio

Receive News & Ratings for VolitionRX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VolitionRX and related companies with MarketBeat.com's FREE daily email newsletter.